Hansa Biopharma names Shannon Campbell, Gregory Perry to board

Bitget2026/09/24 05:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Hansa Biopharma elected Shannon Campbell and Gregory Perry to its board effective Sept. 22, 2026, serving until the next AGM.
Campbell is EVP and chief commercial officer at Merus, leading global commercialization through its acquisition by Genmab.
Perry is CFO at Merus, leading financings and strategic development through the Genmab acquisition; previously CFO at Finch Therapeutics, Novelion Therapeutics.
Michael Bologna, chief investment officer at NovaQuest Capital Management, stepped down from the board.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 20260923:BIT:4495:0) on September 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Hansa Biopharma names Shannon Campbell, Gregory Perry to board

You may also like

Crypto prices